FindTrial
Sign In

Iniparib

DRUG7 trials

Sponsors

Sanofi

Conditions

Advanced Epithelial Ovarian CancerAdvanced Solid TumorsBreast CancerBreast Cancer, MetastaticNon-small Cell Lung Cancer Stage IVPrimary Peritoneal Cancer

Phase 1

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)
CompletedNCT01161836
SanofiAdvanced Solid Tumors
Start: 2010-07-31End: 2011-06-30Updated: 2013-09-24

Phase 2

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer
CompletedNCT00540358
SanofiBreast Cancer
Start: 2007-10-31End: 2010-06-30Updated: 2012-12-28
Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
CompletedNCT00677079
SanofiAdvanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer
Start: 2008-06-30End: 2008-12-31Updated: 2013-10-01
Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer
CompletedNCT01045304
SanofiBreast Cancer, Metastatic
Start: 2010-02-28End: 2012-11-30Updated: 2014-01-14
SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer
CompletedNCT01086254
SanofiNon-small Cell Lung Cancer Stage IV
Start: 2010-05-31End: 2011-12-31Updated: 2013-09-24

Phase 3

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
CompletedNCT00938652
SanofiBreast Cancer
Start: 2009-07-31End: 2012-02-29Updated: 2013-09-19

Unknown Phase

An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer
NCT01130259
SanofiBreast Cancer
Updated: 2013-09-17

Related Papers

PARP and cancer - If it's broke, don't fix it
UNC Libraries2021-12-07
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
2019-06-0612 citations
Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or <i>BRCA1/2</i> mutation-associated breast cancer.
Journal of Clinical Oncology2015-05-205 citations
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.
2014-08-1921 citations
Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
2011-01-05562 citations